| 产品描述: | Mufemilast (Heymay005) is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor (IC50 = 80-120 nM). Mufemilast modulates cytokines upregulated in Behςet’s syndrome (BS). Mufemilast displays a significant inhibitory effect on TNF-α, which is an important proinflammatory cytokine target in the disease process of psoriasis. Mufemilast can be studied in research for diseases such as rheumatoid arthritis, psoriasis and BS. |
| 靶点: |
PDE4 |
| 体外研究: |
Mufemilast (Compound Heymay005) (20 mg/kg/天) 在银屑病异种移植 SCID 小鼠模型中表现出显著的疗效,可减少银屑病面积和表皮厚度、蛋白质表达交换和组织学评分[5]。 |
| 体内研究: |
Mufemilast (Compound Heymay005) (20 mg/kg/天) 在银屑病异种移植 SCID 小鼠模型中表现出显著的疗效,可减少银屑病面积和表皮厚度、蛋白质表达交换和组织学评分。 |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.143 ml |
10.717 ml |
21.435 ml |
| 5 mM |
0.429 ml |
2.143 ml |
4.287 ml |
| 10 mM |
0.214 ml |
1.072 ml |
2.143 ml |
| 50 mM |
0.043 ml |
0.214 ml |
0.429 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |